Breaking News Instant updates and real-time market news.

TNDM

TNDM

, PODD

Insulet

$123.15

1.3 (1.07%)

11:38
07/11/19
07/11
11:38
07/11/19
11:38

Tandem Diabetes a clear beneficiary of Medtronic recall, says Craig-Hallum

Craig-Hallum analyst Alexander Nowak believes Tandem Diabetes (TNDM) and to a lesser extent Insulet (PODD) are the "clear beneficiaries" of the FDA recalling 189,000 Medtronic (MDT) 600-series pumps. The recall should further assist Tandem's share gains over the next several quarters and perhaps years, Nowak tells investors in a research note. And while UnitedHealth (UNH) has an exclusive contract with Medtronic Diabetes, the recall is further data Tandem can use to negotiate with UnitedHealth and argue for inclusion in its network, adds the analyst. He reiterates a Buy rating on shares of Tandem Diabetes with an $84 price target.

TNDM

TNDM

PODD

Insulet

$123.15

1.3 (1.07%)

MDT

Medtronic

$99.79

0.95 (0.96%)

UNH

UnitedHealth

$261.05

13.57 (5.48%)

  • 18

    Jul

  • 05

    Aug

  • 26

    Aug

  • 09

    Sep

  • 12

    Sep

TNDM TNDM

06/17/19
LSCM
06/17/19
NO CHANGE
Target $100
LSCM
Buy
Lake Street reiterates Buy on Tandem Diabetes with $100 price target
Lake Street analyst Brooks O'Neil says shares of Tandem Diabetes fell sharply last week following the release of positive results from two "critical" studies of the t:slim X2 Insulin Pump with Control-IQ Technology. "This reminds us of the reaction of the stock following the release of exceptional Q1 results delivered by Tandem on April 30, 2019," O'Neil tells investors in a research note. While both industry leaders and upstarts are touting "next generation" platforms, only Tandem has conducted a pivotal trial to prove its next gen system's capabilities, O'Neil adds. He reiterates a Buy rating on the shares with a $100 price target.
05/01/19
CHLM
05/01/19
NO CHANGE
Target $84
CHLM
Buy
Tandem Diabetes price target raised to $84 from $70 at Craig-Hallum
Craig-Hallum analyst Alexander Nowak raised his price target for Tandem Diabetes to $84 from $70 as results again surpassed the Street's estimates and the company raised guidance. The analyst reiterates a Buy rating on the shares.
05/13/19
LEER
05/13/19
INITIATION
Target $83
LEER
Outperform
Tandem Diabetes initiated with an Outperform at SVB Leerink
SVB Leerkink analyst Danielle Antalffy initiated Tandem Diabetes with an Outperform and $83 price target.
05/13/19
PIPR
05/13/19
NO CHANGE
Target $78
PIPR
Overweight
Tandem Diabetes' 'rapid' growth can continue, says Piper Jaffray
Piper Jaffray analyst JP McKim reiterates an Overweight rating on Tandem Diabetes with a $78 price target after traveling with management. The company can continue its "rapid" growth though international expansion beyond Animas patients, McKim tells investors in a research note titled "Travel With Management Confirms 'Goldilocks Period' Set To Continue." Further, while Animas supplies stop September 2019, there will be patients who stock up on supplies into 2020 and also some of the patients who took the free MDT 630G in late 2017 will have their old Animas warranty expire and allow them to re-enter the pump market once again, adds the analyst. He also expects Tandem win market share.
PODD Insulet
$123.15

1.3 (1.07%)

06/27/19
JPMS
06/27/19
NO CHANGE
Target $120
JPMS
Neutral
Insulet price target raised to $120 from $90 at JPMorgan
JPMorgan analyst Robbie Marcus raised his price target for Insulet to $120 from $90 following a "bullish" set of investor meetings with management. At only ~$35 for a three-month supply of pods in the pharmacy, with no expensive start-up costs, Dash could be a "game changer," Marcus tells investors in a research note. The analyst believes Insulet's fundamentals are "currently strong," but he keeps a Neutral rating on the shares citing a "rich" valuation and limited upside potential to consensus estimates.
06/28/19
PIPR
06/28/19
NO CHANGE
Target $130
PIPR
Overweight
Insulet price target raised to $130 from $110 at Piper Jaffray
Piper Jaffray analyst JP McKim raised his price target for Insulet to $130 from $110 after hosting meetings with management. The analyst remains positive on the shares, noting that Q2 is the easiest comp of the year. Further, the company's push into the pharmacy is setting up for an acceleration in the U.S. business, and 2020 should bring "notable" gross margin expansion, McKim tells investors in a research note. He remains a buyer of Insulet with an Overweight rating.
06/13/19
UBSW
06/13/19
NO CHANGE
Target $130
UBSW
Buy
Insulet price target raised to $130 from $110 at UBS
UBS analyst Matthew Taylor raised his price target on Insulet to $130 and kept his Buy rating after the company's ADA presentation of data on its Horizon system. The analyst says the data continues to demonstrate "robust clinical outcomes" ahead of its commercial launch in the second half of next year, adding that the shift in the market toward closed loop systems will also allow the company's "form factor and algorithm" to be beneficial. Taylor believes that Insulet's fundamental momentum will allow the company to meet or beat its growth targets for 2019.
06/10/19
06/10/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Cheniere Energy Partners (CQP) downgraded to Sector Perform from Outperform at RBC Capital with analyst Elvira Scotto saying while she views the company's positive FID on Train 6 and updated run-rate guidance positively, she believes these announcements were in line with expectations. 2. At Home Group (HOME) downgraded to Equal Weight from Overweight at Morgan Stanley with analyst Simeon Gutman saying after the company's recent earnings miss and guidance cut that its headwinds appear less transitory than he'd previously thought. 3. Lazard (LAZ) downgraded to Neutral from Buy at UBS with analyst Brennan Hawken saying the company's pipeline of advisory revenue has been "weak." 4. Insulet (PODD) downgraded to Market Perform from Outperform at Northland with analyst Suraj Kalia citing valuation. 5. Realogy (RLGY) downgraded to Equal Weight from Overweight at Stephens with analyst John Campbell saying he believes the company will sees a "depressed multiple" until it can prove the sustainability of its model, which he thinks will take at least a few quarters of consistent earnings growth. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
MDT Medtronic
$99.79

0.95 (0.96%)

06/05/19
06/05/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Roku (ROKU) upgraded to Buy from Neutral at Guggenheim with analyst Michael Morris saying he sees "strong secular tailwinds" for streaming video consumption and believes the company's Q1 results were representative of the core trajectory for its key metrics. 2. Cronos Group (CRON) double upgraded to Buy from Underperform at BofA/Merrill with analyst Christopher Carey saying he has improved confidence that Cronos is near announcing a launch in the U.S., following recent comments by management. 3. Medtronic (MDT) upgraded to Outperform from Market Perform at Wells Fargo with analyst Lawrence Biegelsen saying the company's late stage pipeline will accelerate its growth into fiscal 2021. 4. e.l.f. Beauty (ELF) upgraded to Equal Weight from Underweight at Morgan Stanley with analyst Dara Mohsenian saying he views valuation as more reasonable following the 53% drop in the stock over the last year. 5. FleetCor (FLT) and Wex (WEX) upgraded to Buy from Neutral at Goldman Sachs. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
06/04/19
WELS
06/04/19
UPGRADE
Target $110
WELS
Outperform
Wells Fargo upgrades Medtronic to Outperform with $110 price target
Wells Fargo analyst Lawrence Biegelsen upgraded Medtronic to Outperform from Market Perform and raised his price target for the shares to $110 from $100. The stock closed today up $1.08 to $94.41. The analyst says the company's late stage pipeline will accelerate its growth into fiscal 2021. Further, management has done a better job over the past year of managing consensus expectations, Biegelsen tells investors in a research note. Medtronic is an "accelerating growth story trading at a steep discount to peers," adds the analyst, who sees the valuation gap closing as its growth picks up.
06/14/19
UBSW
06/14/19
NO CHANGE
Target $112
UBSW
Buy
Medtronic price target raised to $112 from $110 at UBS
UBS analyst Matthew Taylor raised his price target on Medtronic to $112 and kept his Buy rating after meeting with it CEO and CFO last week. The analyst notes that the management is "pleased" with the company recent performance as its last year's 11% earnings growth topped its long term target of 8%. Taylor notes that the growth has been driven by operating margin expansion and improving cash flows, with the management also "excited" about the company's product pipeline and "big launches" coming over the next 2 years.
07/11/19
LEHM
07/11/19
NO CHANGE
Target $110
LEHM
Overweight
Medtronic price target raised to $110 from $104 at Barclays
Barclays analyst Kristen Stewart raised her price target for Medtronic to $110 from $104 saying the company's recent debt tender and issuance "modestly helps" its earnings outlook. The analyst keeps an Overweight rating on the shares.
UNH UnitedHealth
$261.05

13.57 (5.48%)

07/11/19
RAJA
07/11/19
NO CHANGE
RAJA
Death of drug rebate rule a win for PBMs and distributors, says Raymond James
After multiple media outlets, including Politico, reported that the Trump Administration has decided to withdraw the drug rebate rule, Raymond James analyst Chris Meekins called the news "a win" for pharmacy benefit managers and drug distributors and "a slight negative" for the pharmaceutical makers. The cost of the proposal to the government was ultimately too high with little guarantee that list prices would go down, said Meekins. However, President Trump hinted something "major" on drug pricing was coming over the next week during his kidney care speech and the analyst thinks the President is planning to move forward with an executive order on pricing. Publicly traded pharmaceutical distributors include McKesson (MCK), Cardinal Health (CAH), Amerisource (ABC) and Patterson (PDCO). Owners of pharmacy benefit managers include CVS Health (CVS), UnitedHealth (UNH), Anthem (ANTM) and Cigna (CI). Publicly traded large cap drugmakers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
07/08/19
BOFA
07/08/19
NO CHANGE
Target $75
BOFA
Neutral
Inspire Medical price target raised to $75 from $65 at BofA/Merrill
BofA/Merrill analyst Bob Hopkins raised his price target for Inspire Medical (INSP) to $75 from $65 after the company announced that United Healthcare (UNH) will provide coverage for Inspire's obstructive sleep apnea therapy as of August 1. In a research note to investors, Hopkins, who maintains a Neutral rating on Inspire, says it takes about 2-4 months for a patient insured by United to work their way through the prior-authorization, but Inspire now estimates that it will take just five days to get approval if a patient meats the restrictions set by United. Hopkins sees potential upside to Street numbers later in 2019 and 2022, but believes his positive outlook is largely reflected in the current stock price.
06/25/19
SBSH
06/25/19
NO CHANGE
SBSH
Molina, Centene have most at stake from Texas Medicaid awards, says Citi
Citi analyst Ralph Giacobbe noted that Texas' "highly anticipated" STAR+PLUS contract for the states' higher acuity Medicaid members is expected to be awarded this Friday, June 28. Among the incumbents in the state, Molina (MOH) and Centene (CNC) have the most at stake, as their respective STAR+PLUS earnings contribute about 7% and 2%, respectively, of his and consensus estimates, Giacobbe tells investors. He estimates that the other incumbents - Anthem (ANTM), Cigna (CI) and UnitedHealth (UNH) - have 1% or less of their earnings at stake, adding that investor expectations are for the incumbents to largely retain business.
06/24/19
ADAM
06/24/19
NO CHANGE
Target $39
ADAM
Buy
HMS Holdings' recent weakness overdone, says Canaccord
Canaccord analyst Richard Close said he believes the recent weakness in HMS Holdings (HMSY) shares is overdone. The weakness was attributed to reports UnitedHealth (UNH) will be buying Equian, a payment integrity services provider. The analyst believes the pullback was based on fears of increased competition and potential risk that HMS will lose UnitedHealth as a customer. He said although both provide integrity services to healthcare, Equian does not provide COB services, which accounted for 66.4% of HMS's revenue. As a result, he does not believe this transaction should raise any concerns. Close reiterated his Buy rating and $39 price target on HMS Holdings shares.

TODAY'S FREE FLY STORIES

TCEHY

Tencent

$0.00

(0.00%)

, MDLA

Medallia

$37.09

(0.00%)

07:31
07/21/19
07/21
07:31
07/21/19
07:31
On The Fly
Opening Day: Start-up DouYou becomes China's biggest Wall Street IPO of 2019 »

Drugmaker Genmab raised…

TCEHY

Tencent

$0.00

(0.00%)

MDLA

Medallia

$37.09

(0.00%)

MIRM

Mirum Pharmaceuticals

$13.51

0.17 (1.27%)

FULC

Fulcrum Therapeutics

$12.49

-0.99 (-7.34%)

PHR

Phreesia

$24.01

-1.15 (-4.57%)

GMAB

Genmab

$18.06

-0.14 (-0.77%)

AMK

AssetMark Financial

$27.71

0.39 (1.43%)

ORCC

Owl Rock

$15.51

0.11 (0.71%)

DOYU

DouYu

$10.50

-0.51 (-4.63%)

NOVA

Sunnova Energy

$0.00

(0.00%)

CSTL

Castle Biosciences

$0.00

(0.00%)

WSG

Wanda Sports

$0.00

(0.00%)

LVGO

Livongo Health

$0.00

(0.00%)

HCAT

Health Catalyst

$0.00

(0.00%)

JNJ

Johnson & Johnson

$130.41

-1.62 (-1.23%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jul

  • 22

    Jul

  • 23

    Jul

  • 23

    Jul

  • 24

    Jul

  • 24

    Jul

  • 31

    Jul

  • 14

    Aug

  • 09

    Sep

  • 16

    Sep

  • 15

    Oct

  • 25

    Jul

  • 25

    Jul

  • 25

    Jul

  • 25

    Jul

  • 26

    Jul

PYPL

PayPal

$118.65

-1.22 (-1.02%)

, V

Visa

$179.18

-1.34 (-0.74%)

08:31
07/20/19
07/20
08:31
07/20/19
08:31
Periodicals
MasterCard, Visa among best stocks to play fintech boom, Barron's says »

The fintech units within…

PYPL

PayPal

$118.65

-1.22 (-1.02%)

V

Visa

$179.18

-1.34 (-0.74%)

MA

MasterCard

$275.51

-1.11 (-0.40%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 24

    Jul

  • 30

    Jul

USB

U.S. Bancorp

$54.98

-0.2 (-0.36%)

, SBNY

Signature Bank

$123.87

1.07 (0.87%)

08:28
07/20/19
07/20
08:28
07/20/19
08:28
Periodicals
KeyCorp, U.S. Bancorp better positioned for Fed rate cut, Barron's says »

KeyCorp (KEY), Signature…

USB

U.S. Bancorp

$54.98

-0.2 (-0.36%)

SBNY

Signature Bank

$123.87

1.07 (0.87%)

KEY

KeyCorp

$17.45

0.15 (0.87%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 29

    Aug

  • 16

    Oct

CMG

Chipotle

$746.80

-17.43 (-2.28%)

08:24
07/20/19
07/20
08:24
07/20/19
08:24
Periodicals
Chipotle stock made 'stunning' comeback, Barron's says »

Chipotle's stock is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 25

    Sep

BYND

Beyond Meat

$176.65

6.28 (3.69%)

07:40
07/20/19
07/20
07:40
07/20/19
07:40
Periodicals
Beyond Meat could spike after earnings, Barron's says »

After rising so…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jul

NFLX

Netflix

$315.10

-10.04 (-3.09%)

07:37
07/20/19
07/20
07:37
07/20/19
07:37
Periodicals
Netflix's problems have only just begun, Barron's says »

Netflix has a problem and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Aug

AMZN

Amazon.com

$1,964.78

-13.57 (-0.69%)

, TGT

Target

$88.02

-0.48 (-0.54%)

07:34
07/20/19
07/20
07:34
07/20/19
07:34
Periodicals
Time to aim higher on Target's stock, Barron's says »

As retailers have…

AMZN

Amazon.com

$1,964.78

-13.57 (-0.69%)

TGT

Target

$88.02

-0.48 (-0.54%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 21

    Aug

  • 19

    Sep

  • 25

    Sep

AMZN

Amazon.com

$1,964.78

-13.57 (-0.69%)

, FDX

FedEx

$167.08

1.69 (1.02%)

07:31
07/20/19
07/20
07:31
07/20/19
07:31
Periodicals
FedEx ups game amid e-commerce growth, Barron's says »

It is time to embrace…

AMZN

Amazon.com

$1,964.78

-13.57 (-0.69%)

FDX

FedEx

$167.08

1.69 (1.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 30

    Jul

  • 31

    Jul

  • 17

    Sep

  • 13

    Nov

AMZN

Amazon.com

$1,964.78

-13.57 (-0.69%)

, MSFT

Microsoft

$136.62

0.33 (0.24%)

07:27
07/20/19
07/20
07:27
07/20/19
07:27
On The Fly
Week in review: How Trump's policies moved stocks »

Catch up on the top…

AMZN

Amazon.com

$1,964.78

-13.57 (-0.69%)

MSFT

Microsoft

$136.62

0.33 (0.24%)

ORCL

Oracle

$57.55

-0.58 (-1.00%)

AZN

AstraZeneca

$40.11

-0.61 (-1.50%)

BMY

Bristol-Myers

$43.32

-0.72 (-1.63%)

LLY

Eli Lilly

$106.75

-1.57 (-1.45%)

GSK

GlaxoSmithKline

$40.97

-0.44 (-1.06%)

JNJ

Johnson & Johnson

$130.41

-1.62 (-1.23%)

MRK

Merck

$81.39

-1.28 (-1.55%)

NVS

Novartis

$93.58

-0.715 (-0.76%)

PFE

Pfizer

$42.78

-0.28 (-0.65%)

RHHBY

Roche

$0.00

(0.00%)

SNY

Sanofi

$41.94

-0.01 (-0.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jul

  • 23

    Jul

  • 23

    Jul

  • 23

    Jul

  • 23

    Jul

  • 24

    Jul

  • 25

    Jul

  • 25

    Jul

  • 25

    Jul

  • 29

    Jul

  • 30

    Jul

  • 30

    Jul

  • 30

    Jul

  • 03

    Aug

  • 06

    Aug

  • 06

    Aug

  • 08

    Aug

  • 18

    Aug

  • 19

    Aug

  • 26

    Aug

  • 27

    Aug

  • 28

    Aug

  • 02

    Sep

  • 09

    Sep

  • 16

    Sep

  • 16

    Sep

  • 20

    Sep

  • 23

    Sep

  • 25

    Sep

  • 02

    Oct

  • 15

    Oct

  • 04

    Nov

BHVN

Biohaven Pharmaceutical

$44.16

-0.61 (-1.36%)

18:12
07/19/19
07/19
18:12
07/19/19
18:12
Hot Stocks
Biohaven receives CRL from FDA for application seeking NURTEC approval »

Biohaven Pharmaceutical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Sep

CE

Celanese

$107.01

0.9 (0.85%)

18:01
07/19/19
07/19
18:01
07/19/19
18:01
Hot Stocks
Celanese announces acetyl intermediates price increases »

Celanese Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

F

Ford

$10.20

-0.06 (-0.58%)

17:48
07/19/19
07/19
17:48
07/19/19
17:48
Periodicals
Ford plans to lay off 185 employees at Ontario plant, Reuters reports »

A union local said that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

  • 23

    Oct

RTN

Raytheon

$178.55

2.45 (1.39%)

17:48
07/19/19
07/19
17:48
07/19/19
17:48
Hot Stocks
Raytheon awarded $191.01M Air Force contract modification »

Raytheon has been awarded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

UTX

United Technologies

$132.37

1.08 (0.82%)

17:44
07/19/19
07/19
17:44
07/19/19
17:44
Hot Stocks
United Technologies awarded $253.71M Air Force contract »

United Technologies has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

LMT

Lockheed Martin

$356.90

0.675 (0.19%)

17:40
07/19/19
07/19
17:40
07/19/19
17:40
Hot Stocks
Lockheed Martin awarded $1.47B Missile Defense Agency contract modification »

Lockheed Martin has been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

ARES

Ares Management

$28.13

-0.305 (-1.07%)

17:33
07/19/19
07/19
17:33
07/19/19
17:33
Syndicate
Breaking Syndicate news story on Ares Management »

Ares Management files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jul

  • 06

    Aug

HAFC

Hanmi Financial

$21.68

-0.105 (-0.48%)

17:33
07/19/19
07/19
17:33
07/19/19
17:33
Hot Stocks
Hanmi Financial to delay release of Q2 results »

Hanmi Financial announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

PAYS

Paysign

$17.49

-0.48 (-2.67%)

17:32
07/19/19
07/19
17:32
07/19/19
17:32
Syndicate
Breaking Syndicate news story on Paysign »

Paysign files $150M mixed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MEOH

Methanex

$43.19

0.83 (1.96%)

17:28
07/19/19
07/19
17:28
07/19/19
17:28
Hot Stocks
Methanex reaches final investment decision on methanol plant in Geismar, LA »

Methanex Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Aug

17:17
07/19/19
07/19
17:17
07/19/19
17:17
Conference/Events
Credit Suisse biotech analysts to hold an analyst/industry conference call »

Biotech Analysts provide…

17:14
07/19/19
07/19
17:14
07/19/19
17:14
Conference/Events
UBS retail/hardlines analyst to hold an analyst/industry conference call »

Retail/Hardlines Analyst…

SHIP

Seanergy Marine

$0.64

-0.0425 (-6.25%)

17:05
07/19/19
07/19
17:05
07/19/19
17:05
Hot Stocks
Seanergy Maritime receives noncompliance notice from Nasdaq »

Seanergy Maritime…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SONM

Sonim

$13.42

0.24 (1.82%)

16:41
07/19/19
07/19
16:41
07/19/19
16:41
Conference/Events
Sonim management to meet with Oppenheimer »

Meetings to be held on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

  • 25

    Jul

  • 26

    Jul

  • 12

    Sep

KINS

Kingstone Companies

$8.81

0.09 (1.03%)

16:30
07/19/19
07/19
16:30
07/19/19
16:30
Hot Stocks
Kingstone names Barry Goldstein CEO »

Kingstone Companies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Aug

  • 09

    Aug

16:30
07/19/19
07/19
16:30
07/19/19
16:30
Options
Preliminary option volume of 22.6M today »

Preliminary option volume…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.